.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently introduced a novel anti-TREM2 agonist antibody named 03O05. This therapeutic candidate shows significant potential for treating Alzheimer’s disease and multiple sclerosis. Unlike traditional antibodies that block receptor shedding, 03O05 preserves physiological processes. Therefore, it increases soluble TREM2 levels while activating neuroprotective microglial functions.
Triggering receptor expressed on myeloid cell-2 (TREM2) signaling is crucial for brain health. Specifically, it promotes the activity of disease-associated microglia. These cells clear toxic debris and maintain neuronal health. However, previous attempts to target this receptor often lowered soluble TREM2 levels. This reduction led to mixed clinical outcomes. Consequently, the team developed 03O05 as a ligand-mimetic solution.
In the 5xFAD mouse model of Alzheimer’s, the treatment yielded impressive results. Chronic administration of the antibody promoted the clearance of filamentous amyloid-beta plaques. Furthermore, it reduced microgliosis while enhancing phagocytosis. These actions effectively ameliorated neuronal dystrophy. Additionally, the researchers observed elevated soluble TREM2 levels in both the serum and brain tissue.
The study also examined the impact on multiple sclerosis using a cuprizone model. During the recovery phase, 03O05 significantly enhanced microglial phagocytosis. This process successfully reduced degraded myelin basic protein. As a result, the antibody promoted remyelination and improved structural integrity. Because this approach does not induce neuroinflammation, it offers a safer therapeutic profile. In summary, shedding-permissive agonism represents a promising strategy for neurodegenerative diseases.
Older agonist antibodies typically block the shedding of the TREM2 receptor. In contrast, 03O05 is shedding-permissive. This allows it to activate the receptor while increasing beneficial soluble TREM2 levels in the brain.
No, the study findings indicate that 03O05 promotes a neuroprotective microglial phenotype. It achieves therapeutic effects without inducing harmful neuroinflammation in mouse models.
The antibody helps clear amyloid-beta plaques and reduces damage to neurons. It also supports microglial health, which is essential for slowing the progression of Alzheimer’s disease.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research identifies 03O05 as a shedding-permissive TREM2 agonist that clears amyloid plaques and promotes remyelination in Alzheimer's and MS mouse models....
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
